Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

36.28

Mkt cap

236B

Volume

160K

High

36.45

P/E Ratio

20.01

52-wk high

42.43

Low

36.03

Div yield

0.04

52-wk low

29.20

The 'Innovation Insights: B-cell Depletion' report highlights Roche's dominance in patent activity for B-cell depletion therapy, with a decrease in new companies filing patents recently.

Portfolio Pulse from

January 17, 2025 | 10:30 am

Roche has received FDA clearance for its VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, a highly-sensitive test for diagnosing B-cell lymphoma. This test is the first of its kind to be clinically approved for assessing the full spectrum of B-cell lymphoma subtypes, aiding in differentiating B-cell cancer from normal immune responses.

Portfolio Pulse from

January 13, 2025 | 6:15 am

Roche has received FDA clearance for its VENTANA DP 600 slide scanner, enhancing its digital pathology capabilities. This approval allows pathologists to use digital images for clinical diagnosis, improving workflow and image quality in pathology labs.

Portfolio Pulse from

January 09, 2025 | 6:15 am

Roche is finalizing its $1.5 billion acquisition of Poseida Therapeutics, a US biopharmaceutical company specializing in immune cell therapies for blood cancer. The deal involves 65 million shares and is set to be completed on Wednesday.

Portfolio Pulse from

January 08, 2025 | 11:45 am

Roche is set to complete its acquisition of U.S. biopharmaceutical company Poseida Therapeutics through its subsidiary Blue Giant Acquisition Corp.

Portfolio Pulse from

January 08, 2025 | 7:00 am

Roche's subsidiary, Blue Giant Acquisition Corp., has completed a tender offer for Poseida Therapeutics, acquiring all outstanding shares at $9.00 per share, with potential additional payments of up to $4.00 per share.

Portfolio Pulse from

January 08, 2025 | 6:30 am

Roche's Vabysmo sales have exceeded USD 4 billion in 2024, capturing over 35% of the global bispecific antibodies market, according to Kuick Research.

Portfolio Pulse from

January 07, 2025 | 4:30 pm

Roche is performing well commercially, but its research and development productivity is still a challenge.

Portfolio Pulse from

January 04, 2025 | 10:15 am

Roche's phase IIb PADOVA study for prasinezumab in early-stage Parkinson's disease did not meet its primary endpoint, indicating a setback in the development of this treatment.

Portfolio Pulse from

December 19, 2024 | 7:45 pm

Roche's Phase IIb study of prasinezumab, conducted in partnership with Prothena, did not meet its primary endpoint but indicated potential clinical benefits for early-stage Parkinson's disease patients.

Portfolio Pulse from

December 19, 2024 | 6:30 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.